STOCK TITAN
  1. Home
  2. News
  3. VIR

Vir Biotechnology Inc - VIR STOCK NEWS

Welcome to our dedicated news page for Vir Biotechnology (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vir Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vir Biotechnology's position in the market.

News
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) presents promising data from Phase 2 SOLSTICE and MARCH trials at AASLD The Liver Meeting®. Initial SOLSTICE data showed 100% HDV RNA reduction with combination therapy. MARCH Part B data demonstrated 3x higher HBsAg loss rates with VIR-3434 + VIR-2218 compared to previous treatment. Investor conference call scheduled for November 13th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences clinical trial
-
News
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Rhea-AI Summary
VIR Biotechnology, Inc. (Nasdaq: VIR) to present new data from Phase 2 trials evaluating VIR-3434 and VIR-2218 for chronic hepatitis B and chronic hepatitis delta patients at AASLD The Liver Meeting®. Late-breaking presentations include end-of-treatment results after 24 weeks of therapy and preliminary results from the Phase 2 SOLSTICE Trial. Investor conference call scheduled for November 13th at 1:30 p.m. PT / 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
conferences clinical trial
-
News
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Rhea-AI Summary
VIR: Vir Biotechnology, Inc. Tops Deloitte Technology Fast 500 List for Second Year, Revenue Growth Fueled by Sotrovimab Sales and Collaboration Partnerships with GSK, Brii Biosciences, and the Bill & Melinda Gates Foundation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
News
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Vir Biotechnology, Inc. provided a corporate update and reported financial results for Q3 2023. The company will present new data at AASLD from Phase 2 clinical trials for chronic hepatitis B and chronic hepatitis delta. They are expanding their focus to autoimmune diseases and immuno-oncology. Jennifer Towne has been appointed as Executive Vice President and Chief Scientific Officer. They secured new BARDA funding for the development of RNA-delivered monoclonal antibodies. As of September 30, 2023, they have $1.7 billion in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
earnings
-
News
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
Rhea-AI Summary
Vir Biotechnology announces the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Towne will lead the company's research function and focus on viral-associated diseases and immune targeting. She brings over two decades of immunology R&D experience and has developed 16 drug candidates throughout her career.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
management
-
News
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
Rhea-AI Summary
Vir Biotechnology's Chief Medical Officer to participate in virtual fireside Q&A at HBV Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
News
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Rhea-AI Summary
Vir Biotechnology announces acceptance of abstracts for presentation at AASLD The Liver Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
Rhea-AI Summary
Vir Biotechnology to provide corporate update and report Q3 financial results on November 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
earnings
-
News
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
Rhea-AI Summary
Vir Biotechnology receives $50 million investment from BARDA to advance development of novel monoclonal antibody candidates and delivery solutions for COVID-19 and pandemic preparedness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
News
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Rhea-AI Summary
Vir Biotechnology initiates Phase 1 trial for VIR-1388, an investigational T cell vaccine for HIV prevention
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
clinical trial
Stock VIR logo
Vir Biotechnology Inc

Nasdaq:VIR

VIR Rankings

#2353 Ranked by Market Cap
#5021 Ranked by Stock Gains
N/A Ranked by Dividends

VIR Stock Data

1.21B
88.97M
14.23%
76.27%
3.67%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Francisco

About VIR

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.